Morris, Ph.D., of the University of Kansas Alzheimer’s Disease Center. “Donepezil significantly reduces the rate of cognitive decline in early [Alzheimer’s disease], and our results suggest ...

May 4, 2009 -- Question: What is Aricept (donepezil), how does it work and when is it used? Answer: Aricept is the brand name for donepezil. Donepezil is one of the cholinesterase inhibitors and ...

NEW YORK (MedscapeWire) Apr 19 — Donepezil ( Aricept) isn't just for Alzheimer's anymore. Results of a randomized, placebo-controlled trial presented April 17 at the American Academy of ...

Alzheimer's drug prescribed off-label could pose risk for some Date: February 25, 2017 Source: University of California - Los Angeles Health Sciences Summary: Donepezil, a medication that is ...

Results The response ratio (MMSE 3+) of donepezil was 37.5% in N2. The combination of donepezil with the psychosocial intervention improved the Vitality Index total score, and Communication ...

Pierre Tariot of the University of Rochester Medical Center, New York, with other clinicians of the ... of people with moderate or severe AD who already were on stable doses of donepezil, as well as ...

The FDA approval was tentative as this product is involved in litigation. Memantine/donepezil extended-release capsules are indicated for the treatment of moderate to severe dementia of the ...

In a Phase 4 trial, 14 months of donepezil treatment failed to slow cognitive decline in depressed patients with MCI. “This is a huge population,” said Murali Doraiswamy, Duke University School of ...

The study, "Combine use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients", was released this month in Communications Medicine, finds that ...

Donepezil, galantamine, rivastigmine and memantine are recommended as possible treatments for some people with Alzheimer's disease. You should be able to have donepezil, galantamine or rivastigmine if ...

According to IQVIA ®, U.S. annual sales for memantine/donepezil tablets, everolimus tablets and rifaximin tablets for the 12 months ended November 2024 were approximately $88 million, $114 ...